On September 18th, bluebird bio (BLUE) announced updated results from their Lenti-D gene therapy studies for cerebral adrenoleukodystrophy ((CALD)) patients. The Phase II/III Starbeam study "ALD-102" is measuring the safety and efficacy of Lenti-D in boys aged 17 and under that suffer from CALD. The company also provided fresh data from their ongoing ALD-103 study of allo-HSCT in boys aged 17 and under with CALD. The follow-up data displays that 88% of treated patients in the Starbeam study did not have any major functional disabilities (MFDs) at two years, and this continued to